title: Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives.
abstract: Metastatic colorectal cancer (mCRC) is a prevalent disease for which combination cytotoxic chemotherapy is the mainstay of treatment. With the use of targeted therapy, including anti-angiogenic agents, there have been significant improvements in overall outcome of patients with mCRC. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor ligand A, is approved for use in mCRC patients in both the first and second lines of therapy. With a better understanding of the disease through molecular profiling, identification of prognostic biomarkers may lead to better patient selection with improved outcomes for those affected by this disease.
authors.affiliation: Department of Medical Oncology, Richard Solove Research Institute and James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
authors.forename: Manojkumar
authors.initials: M
authors.lastname: Bupathi
authors.affiliation: Department of Medical Oncology, Richard Solove Research Institute and James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Ahn
authors.affiliation: Department of Medical Oncology, Richard Solove Research Institute and James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
authors.forename: Tanios
authors.initials: T
authors.lastname: Bekaii-Saab
keywords: VEGF; cancer; colon; rectum